
P R E S S R E L E A S E

Ypsomed Holding AG's annual general meeting approves a par value repayment of CHF 0.60 per share and elects Mr. Gerhart Isler as a new member of the Board of Directors

Burgdorf, 25 June 2008, 6:30 pm – All of the motions tabled by the Board of Directors were approved at today's ordinary general shareholder meeting of Ypsomed Holding AG in Grenchen. The main decisions were:

- approval of the 25.4% profit distribution as a repayment of the par value of CHF 0.60 per share
- election of Mr Gerhart Isler as a member of the Board of Directors

Major shareholder and Chairman of Ypsomed Holding AG, Dr. h.c. Willy Michel, expressed his satisfaction: "With the election of Mr. Gerhart Isler to the Ypsomed Board of Directors, we will gain the services and support of an experienced entrepreneur and Board member; he will certainly be a well qualified replacement for Mr Peter Kappeler whom I wish to thank most sincerely for his excellent commitment to his tasks as member of the Board of Directors over the last 12 years." Mr Gerhart Isler graduated with a lic.oec.publ. degree from the University of Zurich and joined the family publishing business Finanz und Wirtschaft AG as an editor in 1976; he went on to manage the company successfully as a publisher from 1989 onwards. In 2005, he acquired a 32% share in the Jean Frey Verlag before going on to sell the publishing house to the Axel Springer Group in Germany in 2007. Mr Gerhart Isler is a member of the Board of Directors of PubliGroupe, Grand Casino Baden and he is also a member of the board of trustees of the move>med foundation.

Ypsomed makes a minor acquisition in the direct diabetes business in Germany

CEO Richard Fritschi reported to the general meeting on the business numbers for the past business year 2007/2008 and went on to inform the participants of a further acquisition in the direct diabetes business in Germany. CEO Richard Fritschi commented: "Ypsomed has signed a confidential agreement to buy up a smaller competitor of DiaExpert as part of a business handover. This acquisition will take place over the coming months and further strengthen Ypsomed's market position in the direct diabetes business and generate additional sales worth around CHF 3.5 million per annum (Business year 2008/09 additional sales of around CHF 1.8 million)." It is an asset deal and Ypsomed anticipates a total purchase price of around CHF 1.5 million.

Further information is available from Daniel Kusio, Head of Investor & Public Relations at Ypsomed Holding AG. Tel. +41 34 424 41 43 or Tel +41 34 424 41 11. This press release, the annual report for 2007/08 and further documents are available in electronic form at www.ypsomed.com.